Background: The topoisomerase II-targeted drugs, epipodophyllotoxins and anthracyclines, have been shown to induce therapy-related AML (t-AML) characterized by a short latency period after chemotherapy, the absence of prior myelodysplastic syndrome and stereotyped chromosome aberrations. Few reports have been published on patients treated with the anthracenedione mitoxantrone which also targets topoisomerase II. We observed 10 cases of such t-AML over a 7-year-period in breast cancer patients treated with mitoxantrone combined with fluorouracil, cyclophosphamide and regional radiotherapy, and in three cases with vindesine.
Introduction
The increasing numbers of long-term survivors among cancer patients and the widespread use of chemotherapy has resulted in an increased risk of therapy-related acute leukemia, almost always of myelogenous type [1] [2] [3] . The first type of treatment-related leukemia (t-AML) resulted from alkylating agents and radiation therapy. Most cases of alkylating agent-induced acute myelogenous leukemia occurred after a latency period of five to seven years and prior myelodysplasia (MDS) before evolution to overt leukemia. Eighty percent to ninety percent of patients with alkylating agent-related myelodysplastic syndrome (t-MDS) or acute myelogenous leukemia have clonal chromosome aberrations in abnormal cells including monosomy or deletions of the long arm of chromosomes 5 and/or 7 and various rearrangements of chromosomes 3, 12, 17 and 21 [4] [5] [6] .
Certain topoisomerase II-targeted drugs have also recently been reported to induce t-AML with different characteristics. A relationship between the epipodophyllotoxins etoposide and teniposide and t-AML was identified first, at least in combination with cisplatin, alkylating agents or doxorubicin [6] [7] [8] . The anthracyclines doxorubicin and 4-epi-doxorubicin were subsequently shown to induce similar cases of t-AML [6, 9, 10] . These cases differed from t-AMLs induced by alkylating agents by several factors: 1) t-AML was not preceded by a past history of MDS, 2) median time from chemotherapy to AML was shorter (median 2 years), 3) t-AMLs presented with no myelodysplastic features and were easily classified in typical French-American-British (FAB) categories, more frequently M4 or M5, 4) different balanced chromosome aberrations were found, with a high frequency of rearrangements of chromosome band Ilq23, t(8;21), t (15;17) , inv (16) or t(8;16) as in de novo AML [11, 12] . Table 1 . Characteristics of patients and summary of treatments given for breast cancer. -mitoxantrone-fluorouracil-cyclophosphamide;
The role of the anthracenedione derivative mitoxantrone in therapy-related leukemogenesis remains ill-defined. In this study, we report 10 cases of poor prognosis t-AML in breast cancer patients after combinations of mitoxantrone, cyclophosphamide, fluorouracil and regional radiation therapy. We show that such cases of t-AML occurred with low frequency and were similar to t-AML seen after therapy with epipodophyllotoxins and anthracyclines but they seemed to have a poorer prognosis.
Patients and methods
Patients and previous therapy (Table 1) From January 1991 to December 1999, 10 women were referred to our hospital with a past history of treatment for breast cancer with combinations of mitoxantrone, fluorouracil, cyclophosphamide and radiation therapy. 
Laboratory investigations
Peripheral blood smears and bone marrow aspirate were stained with May-Grumvald-Giemsa. AML was diagnosed and classified according to the criteria of the French-American-British (FAB) cooperative working group [13] .
Cytochemical phenotype was established after staining with myeloperoxidase, naphthol AS-D chloracetate esterase, a-naphthyl butyrate esterase and periodic acid Schiff. Lysosyme levels were established in both plasma and urine samples. Immunological phenotype was determined by fluorescence-activated cell sorter analysis using different panels of commercially available monoclonal antibodies.
Karyotypes of leukemic cells were determined after short-term culture. Chromosomes were stained with R or G banding and classified according to the International System for Human Cytogenetic Nomenclature (ISCN 1995) [14] .
Epidemiologic studies
A cohort of 350 patients from a prospective randomized trial was used to estimate the frequency of t-AML after FNC regimen. Women with invasive, non-inflammatory, non-metastatic breast carcinoma were enrolled after informed consent. Inclusion criteria were as follows: age between 18 and 70 years, WHO performance status 0-1, time from surgery < 36 days, conservative surgical procedure and axillary lymph node dissection, stage pTl-pT2, pNl or pNO with other adverse prognostic factor (tumor diameter > 2 cm, estrogen receptor <10 fmol/mg, SBR grade 3, S phase > 10%, vascular or lymphatic invasion). After randomization, they were assigned to receive either a concomitant or sequential FNC regimen (six cycles every three weeks) and radiation therapy. Three hundred twenty-one patients had received six cycles (92.5%). The median follow-up period was 19 months (range 3-39). The probability of developing t-AML was calculated according to the method of Kaplan and Meier [15] , The date of origin was the date of beginning chemotherapy. The date of termination was the date of last follow-up or the date of diagnosis of t-AML. 46.XX [20] 3 cells with non clonal abnormalities 46,XX, t(9;ll)( P 21;q23) [38] / 46,XX,t(9;ll),t(l;6) (q22;p21) [2] 46,XX,t(8;21) (q22;q22) [13] / 46,XX [7] 46 XX [8] Abbreviations: CT -chemotherapy; FAB -French American British; Hb -hemoglobin level; WBC -white blood cell count; CD -cluster of differentiation; CRcomplete remission; ptls -platelet count; ABMT -autologous bone marrow transplantation; ND -not done; ARDS -acute respiratory distress syndrome; GVHD -graft-versus-host disease; TBI -total body irradiation.
Results
The results are summarized in Karyotype was normal in only one patient. One patient had non-clonal abnormalities. Three patients had a breakpoint on chromosome Ilq23 (2 with translocation t(9;ll)(p21;q23) and 1 with deletion del(ll)(ql2q24). In one case with translocation t(9;ll), we found one subclone with additional t(l;6)(q22;q21). Two patients with M4eo had inv(6)(pl3q22). One patient had a I nvariant phenotype and t(15;17)(ql2;q24). One patient with FAB Ml AML had t(8;21)(q22;q22). One patient had deletion del(20)(qll) and additional del(9)(q22q34) in one subclone.
The prognosis of the whole population was poor. Two patients died soon after diagnosis from lung leukostasis and cerebral hemorrhage respectively. Eight patients were able to receive conventional induction chemotherapy, including cytarabine and an anthracycline. Four patients had primary refractory disease and died 4, 5.5, 6 and 9 months after diagnosis, respectively. One patient with M4 AML and t(8;21) died from cerebral hemorrhage on day 30 after induction therapy and one with Ml AML died in CR, two months after diagnosis from septic shock. One died from infection and graft-ver?«.shost disease during allografting. One patient relapsed 60 months after diagnosis and died at 64 months.
Discussion
Ten patients developed t-AML after treatment with combinations of mitoxantrone with cyclophosphamide and fluorouracil and in two cases with vindesine. All had received regional radiation therapy and four had had hormonal therapy with tamoxifen. No patients had received hematopoietic growth factor before AML.
We found no cases in the literature of vinca alkaloidinduced leukemia. Vindesine, like the other vinca alkaloids, vincristine and vinblastin, induces cytotoxicity by virtue of its effect on tubulin, which is the basic subunit of the micro tubules [16] . Unlike epipodophyllotoxins, it does not interact with DNA-topoisomerase II [17] . Vindesine was given to only two of the reported patients, and thus it does not represent a putative leukemogenic agent. Fluorouracil and tamoxifen have been in general use for decades, both alone and in combination, and no increased risk of AML has been described in closely followed cohorts of patients [18, 19] .
Despite prior treatment with cyclophosphamide and radiation therapy, no patient had a presentation that suggested t-AML alkylating agent-related AML and we found no past history of myelodysplasia. Though two patients had reduced dose chemotherapy for breast cancer, they recovered normal hemograms thereafter, and no deletion of chromosome 5 or 7 was found in blast cells.
Cytological findings and karyotype were similar to cases of t-AML seen after treatment with epipodophyllotoxins or anthracyclines [8, 9, 12, [20] [21] [22] . The interval to onset after treatment for breast cancer was short and no preceding myelodysplastic syndrome was diagnosed. As previously reported in t-AML seen after other topoisomerase II inhibitors, blast cells had the same cytological characteristics as de novo AMLs. We found a majority of FAB M3, M4, M5 subtypes, and chromosome abnormalities were similar to genetic changes in t-AMLs seen after epipodophyllotoxins or anthracyclines. A chromosome Ilq23 breakpoint was present in three cases. Translocation of chromosome band Ilq23 was reported to be the most frequent change in t-AML associated with DNA topoisomerase II-targeted drugs [11] . A Ilq23 breakpoint was significantly more frequent in patients with past treatment including topoisomerase II inhibitors [21] . The 'EU concerted action Ilq23 workshop' recently showed that 7% of 550 cases with Ilq23 were secondary to anti-tumor treatment, essentially after epipodophyllotoxins, anthracyclines or both, frequently combined with an alkylating agent or with radiation therapy [22] . Inversion of chromosome 16 was the second most frequent chromosome abnormality in our series, with the classical association with the M4eo phenotype. Inv(16)(pl3q22) was observed in only 6 of 450 cases of t-AML and t-MDS collected in Copenhagen and Chicago [23] , two of which developed in patients previously treated with a DNA topoisomerase inhibitor. t(15;17)(ql2;q24) and t(8;21)(q22;q22) have also been reported in t-AML following topoisomerase II-targeted drugs [9, 24] . Similarities with published findings suggest the responsibility of the topoisomerase II inhibitor mitoxantrone in the genesis of these cases of t-AML, at least in combination with the other drugs and radiation therapy. Mitoxantrone is an anthracenedione derivative that intercalates into DNA and RNA [25] . It is a DNAdamaging agent [26] that interacts with DNA topoisomerase II [27] . Like doxorubicin, mitoxantrone arrests the cell cycle in the G2 and S phases, whereas teniposide and amsacrine, that also interact with DNA topoisomerase II, rapidly trigger DNA degradation in the S phase [28] . We found no reports in the literature that firmly established a role of mitoxantrone in leukemogenesis. In one publication, t-AML was reported after treatment with a combination of mitoxantrone and prednimustine [29] . However, leukemogenesis was attributed to the alkylating agent prednimustine. Of the five cases reported, only one patient had a short latent period, no myelodysplastic phase and M4 FAB phenotype. Karyotyping was not performed in this patient. The four other cases presented as typical alkylating agent-induced AML. One case with FAB Ml and t(16;21)(q24;q22) was reported after a combination of mitoxantrone with etoposide and cyclophosphamide [30] . Because of the combination, no firm conclusion could be drawn on the respective roles of either topoisomerase II inhibitor. In a series of 450 cases of t-AML collected in Copenhagen and Chicago, one pa-tient with inv(16)(pl3q22) had received mitoxantrone combined with cyclophosphamide and fluorouracil [23] . Two cases of t-AML and one case of t-MDS were reported in a series of 59 patients who received mitoxantrone and methotrexate with or without mitomycin as part of adjuvant treatment for breast cancer between 1986 and 1992 [31] . One of four patients with M4 AML and Ilq23 breakpoint reported by Bredeson had received mitoxantrone [32] .
In our series, though t-AML characteristics suggested the responsibility of mitoxantrone, we could not exclude a role of other agents as co-carcinogens. Topoisomerase II inhibitors are always part of regimens including alkylating agents and radiation therapy. Radiation or alkylating agents might have a synergetic effect, as previously suggested with 4-epi-doxorubicin etoposide or doxorubicin [6, 9, 10] . Nevertheless, sufficient differences exist between alkylating agent-or radiotherapy-induced leukemias and t-AML occurring after topoisomerase II inhibitors to conclude that topoisomerase II inhibitors play a major role.
Controversial reports exist on the prognosis of t-AML occurring after topoisomerase II inhibitors. T-AML, with balanced translocations t(8;21), t(15;17), t(9;ll) and inv (16) following treatment with epipodophyllotoxins and anthracyclines, were reported as favorable cytogenetic abnormalities, with similar response rates and survival to those of de novo adult AML [6, 33, 34] . In two series of pediatric epipodophyllotoxin-related t-AML, remission induction was achieved in 80%-90% of patients, but long-term survival rates between 10% and 20% were nonetheless poor [35, 36] . In our series, three patients died of early complications and seven received induction chemotherapy with protocols commonly used in young patients with de novo AML. Three patients died of primary refractory disease, and one relapsed 60 months after treatment and subsequently died. Despite favorable cytological and genetic characteristics at diagnosis, the low CR rate supported a secondary origin. We found no adverse prognostic factor, apart from CD34+ t-AML in three patients that might have predicted poor outcome. Thus, the only difference between our findings and other series in the literature was the topoisomerase II inhibitor involved.
Though karyotype findings in cases of t-AML seen after topoisomerase II-targeted drugs were similar to those observed in de novo AMLs, some differences occurred at the molecular level. In vitro data showed reproducible double strand DNA (dsDNA) cleavage by topoisomerase II inhibitors at a specific site within the AML1 locus, located at chromosome 21q22 band. Site-specific dsDNA cleavage might represent an initial molecular event leading to a chromosomal translocation and t-AML [37] . Nevertheless, differences between t-AML and de novo AML were recently identified in the breakpoint cluster region (BCR) of the MLL gene located on chromosome band 1 Iq23. Seventy-five percent of de novo patient breakpoints mapped in the centromeric half of the BCR, whereas seventy-five percent of the t-AML patient breakpoints mapped in the telomeric half of the BCR [38] . A recent publication showed that the quality of DNA damage appeared to be distinct for each topo II inhibitor on several cell lines [39] . Thus, the specificity of topoisomerase II inhibitors might influence the nature of the DNA alteration. An uncommon rearrangement of the CBFB and MYH11 genes was reported in one patient with t-AML and inv(16) after treatment with mitoxantrone and cyclophosphamide [23] . It can be speculated that breakpoints might vary between t-AML and de novo AML, and also within t-AML according to the topoisomerase II inhibitor involved. The prognosis might be influenced by differences that exist at the molecular level.
It has been suggested that the risk of developing t-AML after treatment with topoisomerase II inhibitors would be at least of the same order of magnitude as after treatment with alkylating agents [40] . We have been using FNC and NVCF regimens in the treatment of breast cancer patients at our center since 1990. Since some patients had been treated at different centers over a wide geographical area, we had no precise information to estimate the total number of patients who were really exposed to mitoxantrone, and hence the risk of developing t-AML after NVCF/FNC. Fortunately, we could analyze the findings of an ongoing prospective trial on adjuvant therapy which compared concomitant versus sequential administration of FNC regimen and regional radiation therapy. Of the 350 patients for whom information was available, 2 patients (included in the present series) developed t-AML 13 and 25 months after inclusion respectively. We calculated the probability of developing t-AML was 0.7% between 25 and 40 months (95% CI: 0.1%-4.5%). Given that the median follow-up period was only 19 months, the probability of developing t-AML reported might be underestimated. A long period of follow-up will be necessary to take into account the risk of developing alkylating agent-related t-AML later.
We conclude that mitoxantrone, at least in combination with cyclophosphamide and/or radiation therapy, was responsible for subsequent development of t-AML in this study. The low incidence must be regarded with caution and a longer follow-up of the prospective cohort is required. The prognosis of the whole population with t-AML was particularly poor. Similarities in the presentation of t-AMLs observed after exposure to epipodophyllotoxins or anthracyclines suggest that interaction with topoisomerase II could be the common denominator for leukemogenesis.
